Search

Your search keyword '"Bonavia, M."' showing total 36 results

Search Constraints

Start Over You searched for: Author "Bonavia, M." Remove constraint Author: "Bonavia, M." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
36 results on '"Bonavia, M."'

Search Results

1. Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

2. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

3. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma

4. Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry

5. The prevalence of sleep impairments and predictors of sleep quality among patients with asthma

6. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

7. COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

8. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

9. Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

10. Urban Health and Wellbeing in the Contemporary City

11. Severe asthma: One disease and multiple definitions

12. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

14. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

15. Characteristics and treatment regimens across ERS SHARP severe asthma registries

16. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

17. Frequency of tiotropium bromide use and clinical features of patients with severe asthma in a real-life setting: Data from the severe asthma network in Italy (sani) registry

18. Characteristics and treatment regimens across ERS SHARP severe asthma registries

19. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

20. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

21. Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI

22. Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

23. The prevalence of sleep impairments and predictors of sleep quality among patients with asthma.

24. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

25. Severe asthma: One disease and multiple definitions

26. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

27. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus.

28. Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.

30. Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up.

31. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy ( SANI ).

32. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis.

33. The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life.

34. Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation.

35. One year of mepolizumab. Efficacy and safety in real-life in Italy.

36. Time Required to Rectify Inhaler Errors Among Experienced Subjects With Faulty Technique.

Catalog

Books, media, physical & digital resources